{{Chembox
| ImageFile = Voclosporin.svg
| ImageSize = 250px
| IUPACName = (3''S'',6''S'',9''S'',12''R'',15''S'',18''S'',21''S'',24''S'',30''S'',33''S'')-30-Ethyl-33-[(1''R'',2''R'',4''E'')-1-hydroxy-2-methyl-4,6-heptadien-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
| OtherNames = VCS, ISA247, Luveniq 
|Section1={{Chembox Identifiers
| CASNo = 515814-01-4
| PubChem = 6918486
| ChemSpiderID = 5293683
| SMILES = O=C1N(C)[C@H](C(=O)N[C@H](C(=O)N(C)CC(=O)N(C)[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N(C)[C@H](C(=O)N(C)[C@H]1C(C)C)CC(C)C)CC(C)C)C)C)C)CC(C)C)C(C)C)CC(C)C)CC)[C@H](O)[C@H](C)C\C=C\C=C
| InChI = 1/C63H111N11O12/c1-25-27-28-29-41(15)53(76)52-57(80)66-44(26-2)59(82)68(18)34-49(75)69(19)45(30-35(3)4)56(79)67-50(39(11)12)62(85)70(20)46(31-36(5)6)55(78)64-42(16)54(77)65-43(17)58(81)71(21)47(32-37(7)8)60(83)72(22)48(33-38(9)10)61(84)73(23)51(40(13)14)63(86)74(52)24/h25,27-28,35-48,50-53,76H,1,26,29-34H2,2-24H3,(H,64,78)(H,65,77)(H,66,80)(H,67,79)/b28-27+/t41-,42+,43-,44+,45+,46+,47+,48+,50+,51+,52+,53-/m1/s1
| InChIKey = BICRTLVBTLFLRD-PTWUADNWBK
| StdInChI = 1S/C63H111N11O12/c1-25-27-28-29-41(15)53(76)52-57(80)66-44(26-2)59(82)68(18)34-49(75)69(19)45(30-35(3)4)56(79)67-50(39(11)12)62(85)70(20)46(31-36(5)6)55(78)64-42(16)54(77)65-43(17)58(81)71(21)47(32-37(7)8)60(83)72(22)48(33-38(9)10)61(84)73(23)51(40(13)14)63(86)74(52)24/h25,27-28,35-48,50-53,76H,1,26,29-34H2,2-24H3,(H,64,78)(H,65,77)(H,66,80)(H,67,79)/b28-27+/t41-,42+,43-,44+,45+,46+,47+,48+,50+,51+,52+,53-/m1/s1
| StdInChIKey = BICRTLVBTLFLRD-PTWUADNWSA-N
  }}
|Section2={{Chembox Properties
| C=63 | H=111 | N=11 | O=12 
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility =
  }}
|Section3={{Chembox Hazards
| MainHazards = 
| FlashPt = 
| AutoignitionPt =
  }}
}}

'''Voclosporin''' is an experimental immunosuppressant drug being [[drug development|developed]] by Aurinia Pharmaceuticals. It is being studied as a potential treatment for [[lupus nephritis]] (LN) and [[uveitis]].<ref>{{Cite web | url = https://www.drugs.com/history/luveniq.html | title = Luveniq Approval Status | quote = Luveniq (voclosporin) is a next-generation calcineurin inhibitor intended for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.}}</ref>  It is an [[analog (chemistry)|analog]] of [[ciclosporin]] that has enhanced action against [[calcineurin]] and greater metabolic stability.<ref>{{cite web | url = http://www.isotechnika.com/dnn/ProductsInDevelopment/Voclosporin/WhatisVoclosporin.aspx | title = What is voclosporin? | publisher = Isotechnika | accessdate = October 19, 2012}}</ref>  Voclosporin was discovered by Robert T. Foster and his team at Isotechnika in the mid 1990s.<ref>{{US patent|6,605,593}}</ref>  Isotechnika was founded in 1993 and merged with Aurinia Pharmaceuticals in 2013.

Initially, voclosporin was a mixture of equal proporations of [[Cisâ€“trans isomerism|''cis'' and ''trans'' geometric isomers]] of amino acid-1 modified cyclosporin.  Later, in collaboration with Roche in [[Basel, Switzerland]], voclosporin's manufacturing was changed to yield the predominantly ''trans'' isomer which possesses most of the beneficial effect of the drug (immunosuppression) in the treatment of organ transplantation and autoimmune diseases.

==References==
{{reflist}}

==External links==
* [http://clinicaltrials.gov/ct2/results?term=voclosporin&Search=Search Voclosporin], [[ClinicalTrials.gov]]

[[Category:Immunosuppressants]]
[[Category:Peptides]]
[[Category:Experimental drugs]]